{"pmid":32312544,"title":"Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic.","text":["Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic.","The risk/benefit ratio of a number of palliative and (neo)adjuvant treatments should be reconsidered during the COVID-19 pandemic. We provide treatment advice as a pragmatic perspective on the risk/benefit ratio in specific clinical scenarios.","Eur Urol","Gillessen, Silke","Powles, Thomas","32312544"],"abstract":["The risk/benefit ratio of a number of palliative and (neo)adjuvant treatments should be reconsidered during the COVID-19 pandemic. We provide treatment advice as a pragmatic perspective on the risk/benefit ratio in specific clinical scenarios."],"journal":"Eur Urol","authors":["Gillessen, Silke","Powles, Thomas"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312544","week":"202017|Apr 20 - Apr 26","doi":"10.1016/j.eururo.2020.03.026","source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664714520104271872,"score":8.518259,"similar":[{"pmid":32250281,"title":"Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","text":["Conducting Clinical Research During the COVID-19 Pandemic: Investigator and Participant Perspectives.","As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support.","JMIR Public Health Surveill","Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P","32250281"],"abstract":["As the medical landscape changes daily with the coronavirus disease (COVID-19) pandemic, clinical researchers are caught off-guard and are forced to make decisions on research visits in their ongoing clinical trials. Although there is some guidance from local and national organizations, the principal investigator (PI) is ultimately responsible for determining the risk-benefit ratio of conducting, rescheduling, or cancelling each research visit. The PI should take into consideration the ethical principles of research, local/national guidance, the community risk of the pandemic in their locale, staffing strain, and the risk involved to each participant, to ultimately decide on the course of action. While balancing the rights and protection of the human subject, we seldom examine patients' views and opinions about their scheduled research visit(s). This article discusses the ethical principles of beneficence and autonomy in helping the decision-making process. We discuss ways to weigh-in local and national guidance, staffing strain, and institutional support into the decision-making process and outline potential changes needed for regulatory bodies depending on the decision. Further, we discuss the need to weigh-in the individual risk-benefit ratio for each participant and present a decision tree to navigate this complex process. Finally, we examine participant and caregiver perspectives on their fears, sense of preparedness, and factors that they consider before deciding whether to keep or postpone the research appointments. This entry also provides PIs ways to support their research participants in both scenarios, including provision of psychological support."],"journal":"JMIR Public Health Surveill","authors":["Padala, Prasad R","Jendro, Ashlyn M","Padala, Kalpana P"],"date":"2020-04-07T11:00:00Z","year":2020,"_id":"32250281","week":"202015|Apr 06 - Apr 12","doi":"10.2196/18887","keywords":["COVID-19","clinical research","ethics","infectious disease","outbreak","pandemic","public health"],"source":"PubMed","weight":0,"_version_":1663352136307572736,"score":122.23074},{"pmid":32232915,"title":"COVID-19 Pandemic - Is Virtual Urology Clinic the answer to keeping the cancer pathway moving?","text":["COVID-19 Pandemic - Is Virtual Urology Clinic the answer to keeping the cancer pathway moving?","The COVID-19 pandemic presents an unprecedented challenge to our National Health Service (NHS) (1). As the need to appropriately direct all efforts towards providing emergency supportive care to those suffering, there will be a knee-jerk tendency to cancel all outpatient activity by NHS trusts. Whilst this appears to be a pragmatic approach to reducing risk of transmission, there will be an unmet cost to those patients who are high-risk and are already on the cancer referral pathway.","BJU Int","Connor, M J","Winkler, M","Miah, S","32232915"],"abstract":["The COVID-19 pandemic presents an unprecedented challenge to our National Health Service (NHS) (1). As the need to appropriately direct all efforts towards providing emergency supportive care to those suffering, there will be a knee-jerk tendency to cancel all outpatient activity by NHS trusts. Whilst this appears to be a pragmatic approach to reducing risk of transmission, there will be an unmet cost to those patients who are high-risk and are already on the cancer referral pathway."],"journal":"BJU Int","authors":["Connor, M J","Winkler, M","Miah, S"],"date":"2020-04-02T11:00:00Z","year":2020,"_id":"32232915","week":"202014|Mar 30 - Apr 05","doi":"10.1111/bju.15061","keywords":["covid-19","telehealth","telemedicine","urology virtual clinic"],"source":"PubMed","topics":["Prevention"],"weight":1,"_version_":1664638455320150018,"score":111.45489},{"pmid":32298029,"title":"How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience.","text":["How to Guarantee the Best of Care to Patients with Cancer During the COVID-19 Epidemic: The Italian Experience.","Italy and the rest of the world are experiencing an outbreak of a novel beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, in Italy, we reorganized the National Health System and prioritized the clinical cancer care scenario, balancing risk of SARS-CoV-2 transmission versus the magnitude of clinical benefit deriving from a specific therapeutic approach. As initial actions, we recommended that routine screening be suspended and that patients with early and advanced cancer be treated as outpatients as much as possible and at the nearest medical center. Patients who need to be hospitalized for cancer treatment were protected from potential SARS-CoV-2 infection by creating a dedicated diagnostic and therapeutic internal pathway for cancer treatment. We implemented reorganization of the hospital networks, based on a hub-and-spoke design. Stronger personal protection was made available for patients with cancer. Because of the extreme burden created by COVID-19, antitumor treatment was initiated only after considering patient performance status, comorbidities, biology of disease, and the likely impact of treatment on outcome. Treatment strategies were discussed in the context of a multidisciplinary tumor board. Treatment decision making balanced risk and benefits of treatment in the context of the specific pandemic level, on a case-by-case basis.","Oncologist","Curigliano, Giuseppe","32298029"],"abstract":["Italy and the rest of the world are experiencing an outbreak of a novel beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In this context, in Italy, we reorganized the National Health System and prioritized the clinical cancer care scenario, balancing risk of SARS-CoV-2 transmission versus the magnitude of clinical benefit deriving from a specific therapeutic approach. As initial actions, we recommended that routine screening be suspended and that patients with early and advanced cancer be treated as outpatients as much as possible and at the nearest medical center. Patients who need to be hospitalized for cancer treatment were protected from potential SARS-CoV-2 infection by creating a dedicated diagnostic and therapeutic internal pathway for cancer treatment. We implemented reorganization of the hospital networks, based on a hub-and-spoke design. Stronger personal protection was made available for patients with cancer. Because of the extreme burden created by COVID-19, antitumor treatment was initiated only after considering patient performance status, comorbidities, biology of disease, and the likely impact of treatment on outcome. Treatment strategies were discussed in the context of a multidisciplinary tumor board. Treatment decision making balanced risk and benefits of treatment in the context of the specific pandemic level, on a case-by-case basis."],"journal":"Oncologist","authors":["Curigliano, Giuseppe"],"date":"2020-04-17T11:00:00Z","year":2020,"_id":"32298029","week":"202016|Apr 13 - Apr 19","doi":"10.1634/theoncologist.2020-0267","source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Italy","Italy","Italian"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"_version_":1664641388275302400,"score":99.83148},{"pmid":32303365,"pmcid":"PMC7156242","title":"Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.","text":["Two known therapies could be useful as adjuvant therapy in critical patients infected by COVID-19.","Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). VitaminC, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitaminC in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves. Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal.","Rev Esp Anestesiol Reanim","Hernandez, A","Papadakos, P J","Torres, A","Gonzalez, D A","Vives, M","Ferrando, C","Baeza, J","32303365"],"abstract":["Pneumonia caused by coronavirus, which originated in Wuhan, China, in late 2019, has been spread around the world already becoming a pandemic. Unfortunately, there is not yet a specific vaccine or effective antiviral drug for treating COVID-19. Many of these patients deteriorate rapidly and require intubation and are mechanically ventilated, which is causing the collapse of the health system in many countries due to lack of ventilators and intensive care beds. In this document we review two simple adjuvant therapies to administer, without side effects, and low cost that could be useful for the treatment of acute severe coronavirus infection associated with acute respiratory syndrome (SARS-CoV-2). VitaminC, a potent antioxidant, has emerged as a relevant therapy due to its potential benefits when administered intravenous. The potential effect of vitaminC in reducing inflammation in the lungs could play a key role in lung injury caused by coronavirus infection. Another potential effective therapy is ozone: it has been extensively studied and used for many years and its effectiveness has been demonstrated so far in multiples studies. Nevertheless, our goal is not to make an exhaustive review of these therapies but spread the beneficial effects themselves. Obviously clinical trials are necessaries, but due to the potential benefit of these two therapies we highly recommended to add to the therapeutic arsenal."],"journal":"Rev Esp Anestesiol Reanim","authors":["Hernandez, A","Papadakos, P J","Torres, A","Gonzalez, D A","Vives, M","Ferrando, C","Baeza, J"],"date":"2020-04-19T11:00:00Z","year":2020,"_id":"32303365","week":"202016|Apr 13 - Apr 19","doi":"10.1016/j.redar.2020.03.004","keywords":["covid-19","ozone","ozono","sars-cov-2","vitamin c","vitamina c"],"source":"PubMed","topics":["Treatment"],"weight":1,"locations":["Wuhan","China"],"countries":["China"],"countries_codes":["CHN|China"],"e_drugs":["Ozone","Ascorbic Acid"],"_version_":1664632934543392768,"score":98.58541},{"pmid":32222433,"pmcid":"PMC7103920","title":"[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","text":["[Guidelines for surgical management of gynaecological cancer during pandemic COVID-19 period - FRANCOGYN group for the CNGOF].","INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus.","Gynecol Obstet Fertil Senol","Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C","32222433"],"abstract":["INTRODUCTION: Recommendations for the management of patients with gynecological cancer during the COVID-19 pandemic period. MATERIAL AND METHOD: Recommendations based on the consensus conference model. RESULTS: In the case of a COVID-19 positive patient, surgical management should be postponed for at least 15 days. For cervical cancer, the place of surgery must be re-evaluated in relation to radiotherapy and Radio-Chemotherapy-Concomitant and the value of lymph node staging surgeries must be reviewed on a case-by-case basis. For advanced ovarian cancers, neo-adjuvant chemotherapy should be favored even if primary cytoreduction surgery could be envisaged. It is lawful not to offer hyperthermic intraperitoneal chemotherapy during a COVID-19 pandemic. In the case of patients who must undergo interval surgery, it is possible to continue the chemotherapy and to offer surgery after 6 cycles of chemotherapy. For early stage endometrial cancer, in case of low and intermediate preoperative ESMO risk, hysterectomy with bilateral annexectomy associated with a sentinel lymph node procedure should be favored. It is possible to consider postponing surgery for 1 to 2 months in low-risk endometrial cancers (FIGO Ia stage on MRI and grade 1-2 endometrioid cancer on endometrial biopsy). For high ESMO risk, it ispossible to favor the MSKCC algorithm (combining PET-CT and sentinel lymph node biopsy) in order to omit pelvic and lumbar-aortic lymphadenectomies. CONCLUSION: During COVID-19 pandemic, patients suffering from cancer should not lose life chance, while limiting the risks associated with the virus."],"journal":"Gynecol Obstet Fertil Senol","authors":["Akladios, C","Azais, H","Ballester, M","Bendifallah, S","Bolze, P-A","Bourdel, N","Bricou, A","Canlorbe, G","Carcopino, X","Chauvet, P","Collinet, P","Coutant, C","Dabi, Y","Dion, L","Gauthier, T","Graesslin, O","Huchon, C","Koskas, M","Kridelka, F","Lavoue, V","Lecointre, L","Mezzadri, M","Mimoun, C","Ouldamer, L","Raimond, E","Touboul, C"],"date":"2020-03-31T11:00:00Z","year":2020,"_id":"32222433","week":"202014|Mar 30 - Apr 05","doi":"10.1016/j.gofs.2020.03.017","keywords":["COVID-19","Cancer gynecologique","Guideline","Gynaecological cancer","Management","Prise en charge","Recommandation"],"source":"PubMed","locations":["ovarian"],"topics":["Treatment"],"weight":1,"_version_":1663352135224393728,"score":98.52057}]}